Dergiler / Turkish Journal of Internal Medicine / 2026 / Volume: 6 Issue: 1

A Case of Acute Lymphoblastic Leukemia Complicated with Sinonasal Mucormycosis Infection

Asuman Şebnem Hacımustafaoğlu(BURSA ULUDAĞ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI)0000-0002-7531-8860
Bedrettin Orhan(BURSA ULUDAĞ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, HEMATOLOJİ BİLİM DALI)0000-0003-3970-2344
Tuba Ersal(BURSA ULUDAĞ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, HEMATOLOJİ BİLİM DALI)0000-0001-5419-3221
Vildan Ozkocaman(BURSA ULUDAĞ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, HEMATOLOJİ BİLİM DALI)0000-0003-0014-7398
Fahir Özkalemkaş(BURSA ULUDAĞ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, HEMATOLOJİ BİLİM DALI)0000-0001-9710-134X
Sayfa
—
Yayın Tarihi
2024-01-29
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

She improved with amphotericin B (5 mg/kg/day) and oral posaconazol (300 mg/day) treatment.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy of lymphoid progenitor cells.
📊
Temel Bulgular & Veri:During treatment of ALL, the patients may be complicated by fatal infections such as sinonasal mucormycosis.
💡
Sonuç & Katkı:She improved with amphotericin B (5 mg/kg/day) and oral posaconazol (300 mg/day) treatment.
🔬Tür:Case Report
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:acute lymphoblastic leukemia · mucormycosis · sinonasal mucormycosis

Abstract

Acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy of lymphoid progenitor cells. During treatment of ALL, the patients may be complicated by fatal infections such as sinonasal mucormycosis. In patients with immunocompromised conditions like haematologic malignancies, mucormycosis can be deadly. Once mucormycosis has been detected, it is critical to act quickly to begin treatment. Amphotericin B, posaconazole, or isavuconazole are the medications of choice. Effective treatment requires a long-term course of therapy. Switching to other effective medications should be considered when the preferred treatment is not working. The factors contributing to mucormycosis must also be treated, such as the underlying conditions (haematologic malignancies). Herein, we aimed to discuss a clinically stable ALL patient complicated with extensive sinonasal mucormycosis. She improved with amphotericin B (5 mg/kg/day) and oral posaconazol (300 mg/day) treatment.

🔖

Bu Makaleye Atıf Yap

Hacımustafaoğlu, A. Ş., Orhan, B., Ersal, T., Ozkocaman, V., Özkalemkaş, F. (2024). A Case of Acute Lymphoblastic Leukemia Complicated with Sinonasal Mucormycosis Infection. Turkish Journal of Internal Medicine, Volume: 6 Issue: 1. https://doi.org/10.46310/tjim.1316471

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Richard-Carpentier G, Kantarjian H, Jabbour E. Recent advances in adult acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2019 Apr;14(2):106-118. doi: 10.1007/s11899-019-00503-1.
  2. Reid G, Lynch JP, Fishbein MC, Clark NM. Mucormycosis. Semin Respir Crit Care Med. 2020 Feb;41(1):99-114. doi: 10.1055/s-0039-3401992.
  3. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019 Mar 21;5(1):26. doi: 10.3390/jof5010026.
  4. Vucicevic BV, Jurlina M, Brailo V, Duric VK, Roncevic P, Bašic KS, Vidovic JD, Gabric D. Oral mucormycosis and aspergillosis in the patient with acute leukemia. Acta Stomatol Croat. 2019 Sep;53(3):274-7. doi: 10.15644/asc53/3/9.
  5. Liang Y, Chen X, Wang J, Guo C, Liu F, Yang J. Oral posaconazole and bronchoscopy as a treatment for pulmonary mucormycosis in pediatric acute lymphoblastic leukemia patient: A case report. Medicine (Baltimore). 2021 Feb 12;100(6):e24630. doi: 10.1097/MD.0000000000024630.
  6. National Comprehensive Cancer Network, Available at: https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed September 20, 2023.
  7. Bonifaz A, Tirado-Sánchez A, Paredes-Farrera F, Moreno-Moreno J, Araiza J, González GM. Oral involvement in mucormycosis. A retrospective study of 55 cases. Enferm Infecc Microbiol Clin (Engl Ed). 2021 Dec;39(10):506-9. doi: 10.1016/j.eimce.2020.09.004.
  8. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, Al-Hatmi AMS, Arikan-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-León DE, Drgona L, Groll AH, Guinea J, Heussel CP, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee DG, Lehrnbecher T, Lmimouni BE, et al.; Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019 Dec;19(12): 405-21. doi: 10.1016/S1473-3099(19)30312-3.
  9. Popa G, Blag C, Sasca F. Rhinocerebral mucormycosis in a child with acute lymphoblastic leukemia: a case report. J Pediatr Hematol Oncol. 2008 Feb;30(2):163-5. doi: 10.1097/MPH.0b013e31815c255f.